Loading…
← CockpitCompetitor Analysis › 600062.SS China Resources Double-Crane Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

China Resources Double-Crane Pharmaceutical Co., Ltd. Class A600062.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other

China Resources-affiliated maker of hospital generic and injectable drugs across a broad range of therapeutic areas.

≈ A Chinese hospital-generics HospiraMomentum strong 74
Mkt cap
$2.35B
US dollars, full cap
Free float
37%
of shares outstanding
$/day
$19.2M
20-day average traded
Fwd P/E
9.3×
forward earnings
ROIC−WACC
+5.4 pp
WACC 5.0%
Hurdle
-14 pp
Req g minus delivered
Next earnings
121 days
19 Mar 2027
Close · CNYCN¥15.08
1D-1.6%
1W-2.5%
1M-7.3%
3M-8.2%
6M-14.2%
YTD-17.6%
1Y-21.6%
ATR %2.1%
52w lowhigh23.7% off high

What China Resources Double-Crane Pharmaceutical does

China Resources-affiliated maker of hospital generic and injectable drugs across a broad range of therapeutic areas.

Sells drugs through distributors to public hospitals, where prices for many generics are set by national volume-based procurement auctions, so winning a contract trades lower prices for guaranteed volume. China Resources, the state-owned conglomerate, controls it and helps with distribution.

In one line: A Chinese hospital-generics Hospira.

Products and services

  • Injectable generic drugs
  • Oral generic drugs
  • Infusion solutions

Customers

  • Public hospitals

Where it sits in the supply chain

  • Pharmaceuticals
  • Generics
  • Hospital injectables

What could go right

  • Hospital drug volume growth
  • China Resources group distribution support

What could go wrong

  • Volume-based procurement price cuts

Moat: none (scale, distribution). Broad generic portfolio and China Resources group distribution support, but limited pricing power.

Headquarters: Beijing, China · Employees: 13,184

Named competitors

China Resources Double-Crane Pharmaceutical at a glance

Size China Resources Double-Crane Pharmaceutical (600062.SS) is a China Health Care company (Pharmaceuticals: Other) with a market value of $2.35B, the 1020th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥15.08 on 18 Nov 2026.

Performance Over six months the shares fell 14.2%, against -0.1% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue fell 1.5% over the last twelve months (peer median +10.2%); the operating margin is 12.6% (peer median 16.4%).

Valuation It trades at 9.3× forward earnings against a peer median of 17.6× (2nd cheapest of 17).

Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 5.4 points above its cost of capital (5.0% WACC).

Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 102600062.SS 87
Six months, rebased to 100: China Resources Double-Crane Pharmaceutical against the median of its 20 peers (local-currency closes).

China Resources Double-Crane Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥10.8BCN¥10.9BCN¥11.1BCN¥11.2BCN¥9.57B
Revenue growth—-2%-1%+17%—
Gross profitCN¥6.46BCN¥5.97BCN¥6.08BCN¥6.11BCN¥4.97B
EBITDAn/aCN¥2.47BCN¥2.37BCN¥2.39BCN¥1.80B
Net incomeCN¥1.57BCN¥1.65BCN¥1.63BCN¥1.67BCN¥1.18B
Free cash flowCN¥985MCN¥1.00BCN¥1.21BCN¥1.33BCN¥984M
Capital expenditureCN¥557MCN¥620MCN¥637MCN¥614MCN¥527M
Total debtCN¥2.14BCN¥1.27BCN¥1.32BCN¥467MCN¥440M

Quarterly statements and history in the cockpit →

China Resources Double-Crane Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%6007503001461112GRANULES600056002317BHC300363002287600216SUDEEPPHRM002603JWEL6472PHMCRON000423600062.SS6-month return →1-month return →
Up and to the right = strong over both horizons. China Resources Double-Crane Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×50×6007503001461112GRANULES002317BHC600216SUDEEPPHRM002603JWEL6472BIOG-BPHMCRON2142600062.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. China Resources Double-Crane Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%6007503001461112GRANULES600056002317BHC300363JWEL6472PHMCRON2142000423600062.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. China Resources Double-Crane Pharmaceutical is the large dot.

China Resources Double-Crane Pharmaceutical competitors and peer comparison

Head to head with its named competitors (600062.SS vs 002755.SZ vs 600276.SS vs 002422.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
China Resources Double-Crane Pharmaceutical 600062.SS$2.35B-14%-1%13%9.3×-9.1%
Beijing Aosaikang Pharmaceutical 002755.SZ$1.60B-31%-13%12%57.4×12.8%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%33.4×13.4%
Sichuan Kelun Pharmaceutical 002422.SZ$10.1B+35%0%9%35.6×6.2%

How China Resources Double-Crane Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

China Resources Double-Crane Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600062.SSPeer medianRank in peer set
1-month return-7.3%-1.2%5th lowest of 21
6-month return-14.2%-0.1%6th lowest of 21
Distance from 52-week high-23.7%-22.6%10th lowest of 21
Revenue growth (TTM)-1.5%+10.2%6th lowest of 21
Operating margin12.6%16.4%8th lowest of 21
Forward P/E9.3×17.6×2nd cheapest of 17
Growth the price implies (Req g, 7 yrs)-9.1%2.1%2nd least demanding of 20
Growth delivered (Del g)+5.3%+10.4%8th lowest of 20
Hurdle (Req g minus delivered)-14.4 pp-8.0 pp5th least demanding of 20
ROIC minus cost of capital+5.4 pp+2.7 pp10th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
China Resources Double-Crane Pharmaceutical 600062.SSChina$2.35B-14%-1%13%9.3×-9.1%+5.3%
China Resources Jiangzhong Pharmaceutical 600750.SSChina$2.27B+4%-10%24%16.5×-1.9%+11.6%
By-health 300146.SZChina$2.56B-1%+10%11%24.7×4.8%+0.6%
Health and Happiness (H&H) International 1112.HKHong Kong$2.15B+108%+24%16%13.2×-1.7%+4.4%
Granules India GRANULES.NSIndia$2.12B+4%+22%17%24.8×23.6%+10.6%
China Meheco 600056.SSChina$1.90B-16%+2%3%n/a-1.3%-2.1%
Jilin Aodong Pharmaceutical 000623.SZChina$2.97B-7%-4%-13%n/a5.0%+1.0%
Guangdong Zhongsheng Pharmaceutical 002317.SZChina$3.00B+11%-14%9%91.7×33.8%+5.9%
Bausch Health Companies BHC.TOCanada$3.27B+66%+10%27%2.0×-14.8%+5.9%
Porton Pharma Solutions 300363.SZChina$1.66B+37%+6%-2%n/a2.1%+10.4%
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%n/a-1.9%+10.4%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
Shijiazhuang Yiling Pharmaceutical 002603.SZChina$3.83B-7%+32%21%17.5×-3.9%-2.2%
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
Dong-E-E-Jiao 000423.SZChina$4.99B+1%+8%29%17.8×-3.7%+14.5%

Questions

Who are China Resources Double-Crane Pharmaceutical's main competitors?
Named competitors: Beijing Aosaikang Pharmaceutical (002755.SZ), Hengrui Medicine (600276.SS), Sichuan Kelun Pharmaceutical (002422.SZ). The cockpit's measured peer set (industry) also includes China Resources Jiangzhong Pharmaceutical (600750.SS), By-health (300146.SZ), Health and Happiness (H&H) International (1112.HK), Granules India (GRANULES.NS), China Meheco (600056.SS), Jilin Aodong Pharmaceutical (000623.SZ).
Is China Resources Double-Crane Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 9.3× against a peer median of 17.6×, 2nd cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has China Resources Double-Crane Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -14.2% against -0.1% for the median peer; over one year -21.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.